Tarbox Family Office’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-36
Closed -$1K 1163
2021
Q4
$1K Buy
+36
New +$1.27K ﹤0.01% 1087

Other funds holding CERE

Tarbox Family Office's CERE Position: Q1 2022 in Review

Tarbox Family Office sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2022, closing a stake of 36 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in CERE in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 107 funds tracked by Wall St. Rank hold CERE as of Q1 2022.

  • Tarbox Family Office reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Tarbox Family Office sold 36 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $1K.
  • Tarbox Family Office first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Tarbox Family Office's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1K in Q4 2021.
  • 107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on Tarbox Family Office's 13F filing for Q1 2022, filed 25 Apr 2022.